Ryan Peters, Kahn Rhrissorrakrai, Prerana Bangalore Parthasarathy, Vadim Ratner, Tanvi P. Gujarati, Meltem Tolunay, Jie Shi, Jeffrey K. Weber, Timothy An-thy Chan, Laxmi Parida, Sara Capponi, Filippo Utro, Tyler Joseph Alban
The rapid growth of quantum computing is driven by promises of performing complex calculations with unprecedented speed; however, current use cases have been limited by quantum hardware and the difficulty of identifying problems that classical computers cannot easily address. Within these constraints, biological problems including drug discovery, protein folding, and precision medicine present an opportunity to understand how current quantum hardware can make advances. In immunology, accurate prediction of cancer neoantigens remains a major challenge, limited by small, noisy datasets and the inability of classical models to generalize. In approaching the problem, we explore multiple noise mitigation techniques, including Pauli twirling and dynamical decoupling, in conjunction with controlled shot-based sampling to stabilize training on real hardware and in a warm start hybrid approach. With these approaches, we demonstrate the use of Quantum Convolutional Neural Networks (QCNNs) for both MHC binding and immunogenicity prediction, including a quantum hardware experiment involving 46 qubits that achieved a 6% increase in classification accuracy with fewer training samples compared to classical approaches. Building on these models, we introduce Quantum Convolutional HLA Immunogenic Peptide Prediction (Q-CHIPP), a combinatorial framework integrating MHC binding and T-cell recognition. It targets HLA-A*02:01-restricted 9-mer peptides and, more accurately, identifies those peptides known to be immunogenic, improving the prognostic impact of predicted neoantigen load. Together, these represent a large-scale application of QCNNs in biomedical modeling, highlighting both the feasibility and promise of quantum machine learning for data-limited biological systems and establishing a scalable foundation for quantum-enhanced biomedical research.
The rapid growth of quantum computing is driven by promises of performing complex calculations with unprecedented speed; however, current use cases have been limited by quantum hardware and the difficulty of identifying problems that classical computers cannot easily address. Within these constraints, biological problems including drug discovery, protein folding, and precision medicine present an opportunity to understand how current quantum hardware can make advances. In immunology, accurate prediction of cancer neoantigens remains a major challenge, limited by small, noisy datasets and the inability of classical models to generalize. In approaching the problem, we explore multiple noise mitigation techniques, including Pauli twirling and dynamical decoupling, in conjunction with controlled shot-based sampling to stabilize training on real hardware and in a warm start hybrid approach. With these approaches, we demonstrate the use of Quantum Convolutional Neural Networks (QCNNs) for both MHC binding and immunogenicity prediction, including a quantum hardware experiment involving 46 qubits that achieved a 6% increase in classification accuracy with fewer training samples compared to classical approaches. Building on these models, we introduce Quantum Convolutional HLA Immunogenic Peptide Prediction (Q-CHIPP), a combinatorial framework integrating MHC binding and T-cell recognition. It targets HLA-A*02:01-restricted 9-mer peptides and, more accurately, identifies those peptides known to be immunogenic, improving the prognostic impact of predicted neoantigen load. Together, these represent a large-scale application of QCNNs in biomedical modeling, highlighting both the feasibility and promise of quantum machine learning for data-limited biological systems and establishing a scalable foundation for quantum-enhanced biomedical research.
Peptide-HLA binding prediction is a critical step in neoantigen identification for personalized cancer immunotherapy and holds significant clinical value. However, the training data available for many HLA alleles are extremely limited, which severely constrains the performance of conventional methods on this task. Parameterized quantum circuits are hypothesized to induce inductive biases beneficial for learning from small datasets, yet their application to biological sequence prediction remains underexplored. To address this, we propose a hybrid quantum-classical neural network (HQNN) specifically designed for peptide-HLA binding prediction. HQNN integrates multi-source biological feature encoding with parallel quantum feature extractors and a quantum-enhanced classifier. On two HLA alleles (A*02:01 and B*07:02), HQNN outperforms a parameter-matched classical CNN baseline across all training sizes, with the performance gap widening as training data decreases. Ablation studies confirm the respective contributions of the quantum feature extraction module and the quantum classifier. In noise-aware simulations, performance degrades only mildly, and such degradation is reasonable and acceptable under realistic quantum hardware noise levels. These results suggest that hybrid quantum-classical architectures can provide practical sample-efficiency gains for immunoinformatics tasks in low-data regimes.
Drug repositioning is a less expensive and time-consuming method than the traditional method of drug discovery. It is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. A key strategy in repositioning approved or investigational drugs is determining the binding affinity of these drugs to target proteins. The large increase in available experimental data has helped deep learning methods to demonstrate superior performance compared to conventional prediction and other traditional computational methods in precise binding affinity prediction. However, these methods are complex and time-consuming, presenting a significant barrier to their development and practical application. In this context, quantum computing (QC) and quantum machine learning (QML) theoretically offer promising solutions to effectively address these challenges. In this work, we introduce a hybrid quantum–classical framework to predict binding affinity. Our approach involves, initially, the implementation of an efficient classical model using convolutional neural networks (CNNs) for feature extraction and three fully connected layers for prediction. Subsequently, retaining the classical module for feature extraction, we implement various quantum and classical modules for binding affinity prediction, which accept the concatenated features as input. Quantum predicted modules are implemented with Variational Quantum Regressions (VQRs), while classical predicted modules are implemented with various fully connected layers. Our findings clearly show that hybrid quantum–classical models accelerate the training process in terms of epochs and achieve faster stabilization. Also, these models demonstrate quantum superiority in terms of complexity, accuracy, and generalization, thereby indicating a promising direction for QML.
Image classification plays a vital role in large-scale data analysis, especially in object recognition tasks using advanced Deep Learning (DL) frameworks. However, the growing complexity and computational demands of modern DL models have introduced challenges related to scalability and efficiency. Quantum Computing (QC) has emerged as a promising alternative, capable of addressing these limitations by leveraging the principles of Quantum Machine Learning (QML). However, many existing QML models require a large number of qubits, which poses limitations within the current Noisy Intermediate-Scale Quantum (NISQ) era. This work introduces a novel Adaptive Quantum Convolutional Neural Network (AQCNN) designed for efficient and scalable image classification within the constraints of NISQ devices. Addressing the limitations of existing QML approaches, particularly the high qubit requirements, AQCNN incorporates a resource-efficient quantum convolutional layer that performs localized quantum filtering using parameterized quantum circuits. A classical preprocessing layer encodes input features to reduce qubit load, followed by quantum embedding and hybrid quantum-classical layers that optimize feature extraction and classification performance. The model leverages an adaptive quantum convolution strategy, minimizing quantum gate depth and circuit complexity while preserving critical spatial hierarchies in image data. Evaluated on benchmark datasets, AQCNN achieved 95.88% accuracy on MNIST and 95.68% on FMNIST, outperforming comparable QML architectures. Additionally, the model supports scalable execution through parallel quantum circuit arrays, enabling practical deployment on current quantum hardware. This architecture demonstrates a significant advance in quantum-assisted image classification, balancing performance with qubit and gate efficiency. The integration of adaptive quantum convolution and hybrid processing not only enhances classification accuracy but also provides a viable path forward for deploying QML solutions under realistic hardware constraints.
Protein-ligand binding affinity is critical in drug discovery, but experimentally determining it is time-consuming and expensive. Artificial intelligence (AI) has been used to predict binding affinity, significantly accelerating this process. However, the high-performance requirements and vast datasets involved in affinity prediction demand increasingly large AI models, requiring substantial computational resources and training time. Quantum machine learning has emerged as a promising solution to these challenges. In particular, hybrid quantum-classical models can reduce the number of parameters while maintaining or improving performance compared to classical counterparts. Despite these advantages, challenges persist: why hybrid quantum models achieve these benefits, whether quantum neural networks (QNNs) can replace classical neural networks, and whether such models are feasible on noisy intermediate-scale quantum (NISQ) devices. This study addresses these challenges by proposing a hybrid quantum neural network (HQNN) that empirically demonstrates the capability to approximate non-linear functions in the latent feature space derived from classical embedding. The primary goal of this study is to achieve a parameter-efficient model in binding affinity prediction while ensuring feasibility on NISQ devices. Numerical results indicate that HQNN achieves comparable or superior performance and parameter efficiency compared to classical neural networks, underscoring its potential as a viable replacement. This study highlights the potential of hybrid QML in computational drug discovery, offering insights into its applicability and advantages in addressing the computational challenges of protein-ligand binding affinity prediction.
Central in drug design is the identification of biomolecules that uniquely and robustly bind to a target protein, while minimizing their interactions with others. Accordingly, precise binding affinity prediction, enabling the accurate selection of suitable candidates from an extensive pool of potential compounds, can greatly reduce the expenses associated to practical experimental protocols. In this respect, recent advances revealed that deep learning methods show superior performance compared to other traditional computational methods, especially with the advent of large datasets. These methods, however, are complex and very time-intensive, thus representing an important clear bottleneck for their development and practical application. In this context, the emerging realm of quantum machine learning holds promise for enhancing numerous classical machine learning algorithms. In this work, we take one step forward and present a hybrid quantum-classical convolutional neural network, which is able to reduce by 20% the complexity of the classical counterpart while still maintaining optimal performance in the predictions. Additionally, this results in a significant cost and time savings of up to 40% in the training stage, which means a substantial speed-up of the drug design process.
The convergence of quantum computing and artificial intelligence (AI) presents a paradigm shift in healthcare, revolutionizing complex biological simulations, genomic data processing, and drug discovery innovations. Traditional computational methods, despite their advancements, often struggle with the sheer scale and complexity of biological data, limiting the speed and accuracy of medical breakthroughs. Quantum computing, with its ability to process vast datasets exponentially faster than classical computers, coupled with AI's predictive capabilities, offers a transformative solution for accelerating biomedical research and clinical applications. This paper explores quantum machine learning’s role in optimizing AI-driven molecular dynamics simulations for drug discovery. By leveraging quantum-enhanced algorithms, researchers can rapidly model molecular interactions, analyze drug-receptor binding affinities, and predict pharmacokinetics with unprecedented precision. Additionally, we examine quantum-assisted deep learning models for deciphering intricate biological mechanisms such as protein folding, epigenetic modifications, and metabolic pathway interactions, enabling more accurate predictions of disease progression and therapeutic targets. Furthermore, the integration of AI-quantum hybrid models in clinical diagnostics and imaging analytics is redefining personalized medicine. Quantum-enhanced deep learning facilitates high-resolution medical imaging, real-time anomaly detection, and optimized radiomic feature extraction, leading to early and more accurate disease diagnosis. In genomics, quantum computing significantly accelerates whole-genome sequencing and mutation analysis, paving the way for tailored treatment strategies based on an individual's genetic profile. Despite its promise, challenges such as quantum hardware limitations, data coherence issues, and ethical considerations must be addressed to ensure the practical implementation of quantum-AI healthcare solutions. This paper provides a comprehensive analysis of the potential, challenges, and future directions of quantum-AI synergy in transforming modern healthcare.